The EpiPen patent is set to expire on 11 September 2025, marking a significant change in the epinephrine delivery market. Mylan acquired EpiPen rights in 2007 and faced backlash for price hikes and lawsuits. In 2020, Mylan merged with Upjohn to form Viatris. A $73.5m settlement was reached in January 2025 for delaying generic EpiPen release.

Dr. Stuart Grant anticipates a rise in generic competitors after the patent expiration, leading to lower prices and increased access for consumers. Viatris may need to cut prices or introduce new financial support programs to stay competitive. Grant suggests exploring next-generation devices and applying for secondary patents for market sustainability.

Competitors can now enhance epinephrine injectors with better ergonomics and innovative technologies like Bluetooth tracking post-patent expiration. New entrants can develop alternative formulations and delivery methods using the expired EpiPen model for accelerated approval pathways, reducing development time and cost. Grant encourages market innovation in this new era.

Read more at Yahoo Finance: EpiPen patent expiry opens new era for innovation